Episode Summary

For parents, caregivers, and anyone living close to cystic fibrosis, this episode asks a painful, hopeful question: what does a CF diagnosis mean for a child born today?

Jeremie Saunders follows two families separated by a generation of science. One entered the world of CF before modulators, when a diagnosis landed like grief and the future felt brutally narrow. The other is raising a child diagnosed through newborn screening in the age of Trikafta, where the prognosis conversation has changed—but fear hasn’t disappeared.

Along the way, we trace the sweat test, newborn screening, pediatric CF care, and the strange emotional terrain of parenting in an era of real medical progress. You’ll hear how Trikafta is reshaping childhood, what still keeps parents up at night, and why hope in cystic fibrosis is wider now—but not yet complete.

This is an episode about the next generation of CF: born into more possibility, still living with uncertainty.

Main Topics & Key Moments

1. The 1989 Baseline & The Long Corridor

• A Strange Year for Hope: Jeremie reflects on his own diagnosis in 1989—the same year scientists discovered the CFTR gene, sparking a wave of hope that evaporated when an immediate cure failed to materialize.
• Asthma or Something Sinister?: Ross Drake recalls the exhausting years spent treating his youngest son, Ryan, for what they thought was asthma, only to watch him cough until he threw up phlegm every night.
• The Elevator Ride: Ross shares the heartbreaking moment he received the call confirming his second son, Stephen, also had CF, and having to leave work to tell his wife.

2. The Science of Sweat & Screening

• Quantitative Pilocarpine Iontophoresis: A deep dive into the classic CF "sweat test." The CFTR protein acts as a cellular gatekeeper; when it fails, chloride cannot re-enter the cells, making CF children famously "salty to the taste."
• The Gray Zone: Understanding the diagnostic numbers: under 30 is clear, 30 to 59 is a medical "maybe," and 60 or higher is the definitive threshold where a family's planned future disappears.
• The Battle for Newborn Screening: How Cystic Fibrosis Canada fought a province-by-province bureaucratic war to mandate infant screening, allowing babies like Miles to be flagged and treated weeks after birth rather than years.

3. The Generational Divergence

• Diagnosis as Loss vs. Diagnosis Tinted with Hope: While Ross’s generation faced a relentless schedule of prevention and a median life expectancy of just 37 years, Brittany was told that while the diagnosis was unfortunate, Miles "couldn't have been born at a better time."
• Trikafta as a Childhood Landscape: For the new generation, CFTR modulators aren't a mid-life rescue mission; they are the baseline. The drug targets the underlying protein defect, moving the line from symptom management to true physical transformation.

4. The Enzyme Revelation

• Blowing the Medical Mind: Brittany shares a stunning clinical update: because Miles started Trikafta at such a young stage, his pancreas has recovered enough that he has been completely taken off pancreatic enzymes.
• Preserving the Organ: The medical frontier explores how introducing modulators to infants might prevent chronic organ damage before it ever starts.

Key Quotes

• "Parenting with CF meant building your life around prevention, because medicine couldn't yet offer transformation." — Host (Jeremie)
• "I got to go home now and tell my wife, my other son has CF." — Ross Drake
• "As unfortunate as it is that he has been diagnosed with CF, he couldn't have been born at a better time." — Brittany Hollowink
• "And this has just been within the last three months we've been able to completely take him off his pancreatic enzymes... He's been doing just fine and it's blowing my mind." — Brittany Hollowink

Hosted on Acast. See acast.com/privacy for more information.